CBD Effects on Cat Aggression: New 2026 Study Results

Introduction

Research on cannabidiol (CBD) for pets now provides specific, quantitative evidence for its use in veterinary behavior medicine. A 2026 clinical trial from Thailand directly compared CBD to a standard pharmaceutical for feline aggression, while a parallel survey from France captures how owners perceive and use these products. These studies move the conversation beyond anecdote to controlled data.

CBD Matches Standard Drug for Feline Aggression Without Appetite Loss

Researchers from Akkhraratchakumari Veterinary College led by Supanta J designed a trial to test a common concern in behavioral medicine. Owner-directed aggression in cats often leads to prescriptions for fluoxetine, a selective serotonin reuptake inhibitor (SSRI). A frequent and problematic side effect is transient anorexia, which can cause pet owners to stop treatment.

The team enrolled 100 cats exhibiting this aggression in a single-blind trial. They assigned the cats to one of five groups for 4 to 8 weeks: a control group receiving no treatment, groups receiving CBD at 1 mg/kg/day or 2 mg/kg/day, a group receiving fluoxetine at 0.5-1 mg/kg/day, and a group receiving a combination of both compounds. The primary measure was a change in a standardized aggression score.

Results showed all active treatment groups had significantly lower aggression scores than the control group. Critically, there was no statistical difference in efficacy between the treatments. CBD at the 1 mg/kg/day dose performed as well as fluoxetine. The study authors note that “CBD at 1 mg/kg/day showed efficacy comparable to fluoxetine without anorexic effects.” This finding directly addresses a major limitation of current first-line therapy.

Owner Surveys Reveal Motivations and a Preference for Veterinary Advice

While clinical trials establish efficacy, real-world use patterns are captured in surveys. Audrey Besegher and colleagues at Université Paris Nanterre surveyed 2050 French pet owners about their perception and use of CBD for dogs and cats.

They found CBD use was “not widespread but remained notable.” Owners who chose CBD were primarily driven by the desire for a natural product and the intention to manage specific conditions. Anxiety and pain were the most frequently cited reasons for use. This aligns with the Thai study’s focus on anxiety-related aggression. Owners reported a higher level of satisfaction and perceived effectiveness when they had discussed CBD use with their veterinarian first.

The survey also identified barriers. A lack of information about the product and uncertainty about regulations were common reasons owners chose not to use CBD. This highlights a communication gap between emerging research, veterinary knowledge, and public understanding.

The Mechanisms Behind CBD’s Potential Effects in Pets

Cannabidiol does not induce a “high”; its action is more subtle. It interacts with the endocannabinoid system (ECS), a network of receptors and signaling molecules found in all mammals. The ECS helps regulate mood, pain perception, inflammation, and appetite.

Unlike THC, which strongly activates certain ECS receptors, CBD has a more modulatory effect. It is thought to increase the availability of the body’s own endocannabinoids and influence other receptor systems, like serotonin receptors. This action on serotonin pathways—similar to but distinct from drugs like fluoxetine—may explain its observed anxiolytic effects in the feline aggression trial. Its influence on other receptors likely underpins its reported use for pain and inflammation, areas explored in other studies like those on canine epilepsy and osteoarthritis pain management.

Applying Evidence to Practice: Dosage, Safety, and Consultation

The Thai trial provides a specific, evidence-based dosing benchmark for one condition: 1 mg of CBD per kg of body weight per day for feline aggression. This is a valuable starting point for veterinary discussions. Dosing is not one-size-fits-all and can vary based on the product’s formulation and the condition being treated.

Safety is paramount. The study reported no anorexic effects from CBD, but potential side effects like mild sedation or gastrointestinal upset are possible. Product quality varies significantly. Owners should seek products with a certificate of analysis (COA) from an independent lab to verify CBD content and the absence of contaminants like heavy metals or THC, which is toxic to pets. The survey data strongly supports involving a veterinarian. A vet can rule out underlying medical causes for behavioral or pain issues—such as silent urinary tract infections causing agitation—and help monitor for drug interactions, particularly if a pet is on other medications.

Conclusion

Controlled research, such as the 2026 trial from Walailak University, demonstrates that CBD can be an effective tool in veterinary behavior with a distinct safety advantage regarding appetite. Owner surveys confirm its use for anxiety and pain, and underscore the need for professional guidance. For pet owners, this evolving evidence base supports informed, veterinarian-guided conversations about CBD as part of a comprehensive care plan.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41752943/
https://pubmed.ncbi.nlm.nih.gov/41389569/
https://pubmed.ncbi.nlm.nih.gov/40968477/